+

WO2003086310A2 - Prevention of brain inflammation as a result of induced autoimmune response - Google Patents

Prevention of brain inflammation as a result of induced autoimmune response Download PDF

Info

Publication number
WO2003086310A2
WO2003086310A2 PCT/US2003/011316 US0311316W WO03086310A2 WO 2003086310 A2 WO2003086310 A2 WO 2003086310A2 US 0311316 W US0311316 W US 0311316W WO 03086310 A2 WO03086310 A2 WO 03086310A2
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid
antibodies
accordance
disease
receptors
Prior art date
Application number
PCT/US2003/011316
Other languages
French (fr)
Other versions
WO2003086310A3 (en
Inventor
Beka Solomon
Original Assignee
Ramot At Tel Aviv University Ltd.
Mcinnis, Patricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel Aviv University Ltd., Mcinnis, Patricia filed Critical Ramot At Tel Aviv University Ltd.
Priority to US10/510,820 priority Critical patent/US20070134247A9/en
Priority to AU2003226356A priority patent/AU2003226356A1/en
Publication of WO2003086310A2 publication Critical patent/WO2003086310A2/en
Publication of WO2003086310A3 publication Critical patent/WO2003086310A3/en
Priority to US12/467,931 priority patent/US20090280114A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Definitions

  • the present invention is directed to methods for reducing risk of inflammation as a result of induced autoimmune response and particularly as a result of immunotherapy of diseases characterized by amyloid aggregation.
  • a peptide which may be an entire amyloid peptide or a portion thereof, is administered in order to raise antibodies in vivo, which antibodies will bind to the soluble and/or the aggregated amyloid.
  • - Passive vaccination involves administering antibodies specific to the amyloid peptide directly. These procedures are preferably used for the treatment of Alzheimer's disease by diminishing the amyloid plaque or slowing the rate of deposition of such plaque.
  • Antibody-antigen complexes initiate the inflammatory response and are central to the pathogenesis of tissue injury.
  • the immune complex triggers inflammation, which is initialized by cell bound Fc receptors, and is then amplified by cellular- mediators and activated complement.
  • the accepted model of inflammation is one in which antibodies bind their antigen, forming immune complex, which in turn binds and activates the complement by means of the "classical pathway" (Clynes et al, 1995) .
  • FcR immunoglobulin
  • the diversity of these receptors is reflected in a wide variety of biological responses immediately upon their binding of IgG-antigen complexes, including phagocytosis, endocytosis, antibody-dependent cell-mediated cytotoxicity (ADCC) , release of inflammatory mediators and regeneration of B-cell function (Clynes et al, 1995) .
  • the present invention solves the problem of increased risk of brain inflammation as a result of induced autoimmune response by eliminating the inflammation pathway initiated by binding of an immune complex to an Fc receptor.
  • the present invention is based on the realization that the brain inflammation that caused the cessation of the clinical trials for AN-1792 was most likely caused by the inflammatory reaction initiated by binding of the immune complex to Fc receptors.
  • This immune reaction could be stopped before it begins by one of two techniques in accordance with the present invention.
  • the first such technique is to block the Fc receptors prior to commencing the immunotherapy.
  • the preferred way to do this is to administer a large dose of IVIg, i.e., human intact intravenously administered immunoglobulin.
  • Intravenous immunoglobulins have become an established component of immunomodulatory therapy in neurological autoimmune diseases, including inflammatory diseases of the central nervous system (CNS) (van der Meche and van Doom, 1997/ Dalakis, 1999; Stangel et al, 1999) .
  • This embodiment of the present invention is based on the realization that IVIg can be used as a preventive step prior to immunotherapy designed to cause antibodies against amyloid- ⁇ to come into contact with aggregated or soluble amyloid- ⁇ in vivo, regardless of whether the antibodies are directly administered or generated in vivo by administering an antigenic peptide, such as an amyloid peptide.
  • the second method to avoid binding of the immune complex to Fc receptors is to use antibodies that are devoid of Fc regions.
  • antibodies devoid of Fc regions include Fab, F(ab) 2 and/or scFv antibodies.
  • Such antibodies will still bind to the amyloid or amyloid plaque, but the immune complexes will not start the inflammation sequence because they will not bind to Fc receptors.
  • Alzheimer's disease Parkinson's disease, multiple sclerosis
  • glia especially microglia, become activated (a process termed reactive gliosis) following an initial wave of neuronal death resulting from traumatic injury, exposure to neurotoxins, and ischemia in the brain.
  • Activated microglia produce a variety of proinflammatory and cytotoxic factors including cytokines.
  • Microglia are very sensitive to changes in the CNS microenvironment and rapidly become activated in virtually all conditions that disrupt normal neuronal functions.
  • microglia Upon activation, microglia secrete a range of immune regulatory peptides as cytokines and non-specific inflammatory mediators, e.g., nitric oxide, and become phagocytic, thus representing the latent scavenger cells of the CNS (Liu et al, 2001) .
  • IVIg intravenous immunoglobulins
  • MS multiple sclerosis
  • ADAM acute demyelinating encephalomyelitis
  • IVIg intravenous immunoglobulins
  • Fc receptor-mediated phagocytosis was inhibited by IVIg, presumably by blockage of the Fc receptor (Stangel et al, 2001) .
  • IVIg in addition to known effects on the peripheral immune system, may also be used to modulate the local immune reaction in CNS inflammatory disease.
  • Phages as a delivery system of scFv and Fab are able to remove the plaque via efflux from brain-blood or other peripheral membranes.
  • a phage delivery system, or any other carrier for the antibody which potentiates efflux of the immune system of the immune complex is a preferred embodiment of the present invention.
  • the IVIg injection method for blocking the majority of Fc receptors in microglia, prior to the i.p or i.n. injection of whole antibodies should be undertaken in order to avoid over-activation of microglia.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A disease characterized by amyloid aggregation in a patient may be prevented or treated by causing antibodies against a peptide component of the amyloid deposit to come into contact with the aggregated or soluble amyloid. In order to decrease the risk of inflammation in such a method, the Fc receptors of the patient are blocked, preferably by administration of an effective amount of IVIg, prior to the procedure of causing the antibodies to come into contact with the amyloid.

Description

PREVENTION OF BRAIN INFLAMMATION AS A RESULT OF INDUCED
AUTOIMMUNE RESPONSE
FIELD OF THE INVENTION [0001] The present invention is directed to methods for reducing risk of inflammation as a result of induced autoimmune response and particularly as a result of immunotherapy of diseases characterized by amyloid aggregation.
BACKGROUND OF THE INVENTION [0002] Methods for the prevention or treatment of diseases characterized by amyloid aggregation in a patient have been proposed which involve causing antibodies against a peptide component of an amyloid deposit to come into contact with aggregated or soluble amyloid. See W099/27944 of Schenk and U.S. patent 5,688,651 of Solomon, the entire contents of each of which being hereby incorporated herein by reference. The antibodies may be caused to come into contact with the soluble or aggregated amyloid by either active or passive vaccination. In active vaccination, a peptide, which may be an entire amyloid peptide or a portion thereof, is administered in order to raise antibodies in vivo, which antibodies will bind to the soluble and/or the aggregated amyloid.- Passive vaccination involves administering antibodies specific to the amyloid peptide directly. These procedures are preferably used for the treatment of Alzheimer's disease by diminishing the amyloid plaque or slowing the rate of deposition of such plaque.
[0003] It has been reported that clinical trials had been undertaken by Elan Corporation and Wyeth-Ayerst Laboratories of a vaccine to test such a process. The compound being tested was AN-1792. This product has been reported to be a form of β-amyloid 42. However, in February of 2002, the two companies announced that the vaccine study had been halted after more than a dozen participants developed severe brain inflammation. In view of the promising prospects of such an immunotherapy program, particularly in light of the animal data set forth in W099/27944 and Schenk et al (1999), it would be of great benefit to find a way to allow the clinical trials of this immunotherapeutic method to continue without the risk of brain inflammation.
[0004] Antibody-antigen complexes initiate the inflammatory response and are central to the pathogenesis of tissue injury. The immune complex triggers inflammation, which is initialized by cell bound Fc receptors, and is then amplified by cellular- mediators and activated complement. The accepted model of inflammation is one in which antibodies bind their antigen, forming immune complex, which in turn binds and activates the complement by means of the "classical pathway" (Clynes et al, 1995) .
[0005] The classical model for this immuno athological cascade, the Arthus reaction, was reinvestigated with a murine strain deficient in Fc receptor expression (Sylvestre et al, 1994) . Despite normal inflammatory responses to other stimuli, the inflammatory response to immune complexes was markedly attenuated. These results suggest that the immune complex-triggered inflammation is initiated by cell bound Fc receptors and is then amplified by cellular mediators and activated complement. These results redefine the inflammatory cascade and may offer other approaches for the study and treatment of immunological injury.
[0006] Cell membrane receptors specific for the Fc portion of immunoglobulin (FcR) play an important role in immunity and resistance to infection, providing a system that couples antibody-antigen interaction with cellular effector mechanisms. Distinct cell membrane FcRs have been described for all classes of immunoglobulins . The FcRs comprise a multi-membered family of structurally homologous but distinct receptors and are expressed on the vast majority of leukocytes. The diversity of these receptors is reflected in a wide variety of biological responses immediately upon their binding of IgG-antigen complexes, including phagocytosis, endocytosis, antibody-dependent cell-mediated cytotoxicity (ADCC) , release of inflammatory mediators and regeneration of B-cell function (Clynes et al, 1995) .
SUMMARY OF THE INVENTION [0007] The present invention solves the problem of increased risk of brain inflammation as a result of induced autoimmune response by eliminating the inflammation pathway initiated by binding of an immune complex to an Fc receptor. The present invention is based on the realization that the brain inflammation that caused the cessation of the clinical trials for AN-1792 was most likely caused by the inflammatory reaction initiated by binding of the immune complex to Fc receptors. This immune reaction could be stopped before it begins by one of two techniques in accordance with the present invention. The first such technique is to block the Fc receptors prior to commencing the immunotherapy. The preferred way to do this is to administer a large dose of IVIg, i.e., human intact intravenously administered immunoglobulin. [0008] Intravenous immunoglobulins (IVIg) have become an established component of immunomodulatory therapy in neurological autoimmune diseases, including inflammatory diseases of the central nervous system (CNS) (van der Meche and van Doom, 1997/ Dalakis, 1999; Stangel et al, 1999) . This embodiment of the present invention is based on the realization that IVIg can be used as a preventive step prior to immunotherapy designed to cause antibodies against amyloid- β to come into contact with aggregated or soluble amyloid-β in vivo, regardless of whether the antibodies are directly administered or generated in vivo by administering an antigenic peptide, such as an amyloid peptide.
[0009] The second method to avoid binding of the immune complex to Fc receptors is to use antibodies that are devoid of Fc regions. Thus, rather than generating intact antibodies in vivo by active vaccination, one would administer antibodies by passive vaccination but using antibodies devoid of Fc regions. Examples of antibodies devoid of Fc regions include Fab, F(ab)2 and/or scFv antibodies. Such antibodies will still bind to the amyloid or amyloid plaque, but the immune complexes will not start the inflammation sequence because they will not bind to Fc receptors.
[0010] While it is believed that the immune complexes using antibodies without an Fc receptor will be cleared by other mechanisms than the Fc receptor mechanism, other means may be provided to effect or promote such clearance. For example, it is known that filamentous phages as a delivery system of scFv and Fab are able to remove the plaque by efflux from brain- blood or other peripheral membranes. Other carrier material for the antibodies devoid of Fc can also be used to promote efflux of the immune complexes .
DETAILED DESCRIPTIONS OF PREFERRED EMBODIMENTS
Blocking of Fc Receptors Prior to Immunization by Intravenous Immunoglobulin (IVIg) Administration
[0011] Microglial activation is frequently observed in the pathogenesis of neurodegenerative diseases, such as
Alzheimer's disease, Parkinson's disease, multiple sclerosis,
AIDS dementia complex and amyotrophic lateral sclerosis. In addition, glia, especially microglia, become activated (a process termed reactive gliosis) following an initial wave of neuronal death resulting from traumatic injury, exposure to neurotoxins, and ischemia in the brain. Activated microglia produce a variety of proinflammatory and cytotoxic factors including cytokines. Microglia are very sensitive to changes in the CNS microenvironment and rapidly become activated in virtually all conditions that disrupt normal neuronal functions. Upon activation, microglia secrete a range of immune regulatory peptides as cytokines and non-specific inflammatory mediators, e.g., nitric oxide, and become phagocytic, thus representing the latent scavenger cells of the CNS (Liu et al, 2001) .
[0012] Controlled trials in multiple sclerosis (MS) and case reports in acute demyelinating encephalomyelitis (ADEM) have shown that intravenous immunoglobulins (IVIg) are of therapeutic benefit in CNS inflammatory diseases. It has been shown that Fc receptor-mediated phagocytosis was inhibited by IVIg, presumably by blockage of the Fc receptor (Stangel et al, 2001) . These different effects may protect oligodendrocytes from antibody-mediated phagocytosis and on the other hand could terminate the immune reaction by induction of apoptosis. In accordance with the present invention, IVIg, in addition to known effects on the peripheral immune system, may also be used to modulate the local immune reaction in CNS inflammatory disease.
[0013] Similarly, γ-chain-deficient mice are completely resistant to the development of experimental immune thrombocytopenia induced by mouse anti-platelet antibodies. These data support the concept of the present invention that Fc receptors play in integral role in the pathogenesis of type II hypersensitivity and suggest the concomitant potential therapeutic benefits of Fc receptor blockade.
Passive Vaccination Approach May Be Based on Delivery (i.p or i.n) of Antibodies Devoid of Fc Regions, Namely Fab, F(ab)2 and/or scFv.
[0014] The laboratory of the present inventor has previously proved that the Fc region is not involved in disaggregation of amyloid plaque, as scFv devoid of Fc performed similarly to whole antibodies in disaggregation of β-amyloid. Accordingly, such antibodies are preferred to intact antibodies as they will not cause initiation of the inflammatory cascade as they will not be bound by Fc receptors.
[0015] Phages as a delivery system of scFv and Fab are able to remove the plaque via efflux from brain-blood or other peripheral membranes. Thus, use of a phage delivery system, or any other carrier for the antibody which potentiates efflux of the immune system of the immune complex is a preferred embodiment of the present invention. [0016] If whole antibodies bound to phage are used for i.n. administration, the IVIg injection method for blocking the majority of Fc receptors in microglia, prior to the i.p or i.n. injection of whole antibodies should be undertaken in order to avoid over-activation of microglia. [0017] The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention. Thus the expressions "means to..." and "means for...", or any method step language, as may be found in the specification above and/or in the claims below, followed by a functional statement, are intended to define and cover whatever structural, physical, chemical or electrical element or structure, or whatever method step, which may now or in the future exist which carries out the recited function, whether or not precisely equivalent to the embodiment or embodiments disclosed in the specification above, i.e., other means or steps for. carrying out the same functions can be used; and it is intended that such expressions be given their broadest interpretation.
REFERENCES
Clynes et al, "Cytotoxic antibodies trigger inflammation through Fc receptors", Immunity, 3:21-26 (1995)
Dalakas MC, "Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines", Muscle Nerve 22:1479- 1497 (1999)
Liu et al, "Molecular consequences of activated microglia in the brain: overactivation induces apoptosis", J Neurochem 77:182-189 (2001) Schenk et al "Immunization with amyloid-beta attenuates
Alzheimer-disease-like pathology in the PDAPP mouse", Nature, 400 (6740) : 116-117 (1999)
Stangel et al, "Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases", Arch Neurol 56:661-663 (1999)
Stangel et al, "Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vi tro via Fc receptors", J Neuroimmuno1 112:63-71 (2001)
Sylvestre et al, "Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade", Science, 265:1095 (1994) van der Meche and van Doom, "The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders", Muscle Nerve 20:136-147 (1997)

Claims

WHAT IS CLAIMED IS:
1. In a method for the prevention or treatment of a disease characterized by amyloid aggregation in a patient by causing antibodies against a peptide component of an amyloid deposit to come into contact with aggregated or soluble amyloid, the improvement by which risk of inflammation is diminished, comprising: prior to the procedure of causing the antibodies to come into contact with the amyloid, blocking Fc receptors .
2. A process in accordance with claim 1, wherein said blocking of Fc receptors is accomplished by intravenously administering an effective amount of immunoglobulin (IVIg) to the patient.
3. A process in accordance with claim 2, wherein the IVIg is intact human polyclonal immunoglobulin.
4. A process in accordance with claim 1, wherein the disease characterized by amyloid aggregation is a disease of the central nervous system.
5. A process in accordance with claim 4, wherein the disease is Alzheimer's disease.
6. In a method for prevention or treatment of a disease characterized by amyloid aggregation in a patient by administering antibodies against a peptide component of an amyloid deposit, the improvement by which risk of inflammation is diminished, comprising: using as said antibodies, antibodies devoid of Fc regions .
7. A method in accordance with claim 6, wherein said antibodies are Fab, F(ab)2 and/or scFv antibodies.
8. A method in accordance with claim 6, wherein said antibodies are presented on a carrier which potentiates efflux of the antibody amyloid complex.
9. A method in accordance with claim 8, wherein said carrier is a filamentous phage.
10. A process in accordance with claim 6, wherein the disease characterized by amyloid aggregation is a disease of the central nervous system.
11. A process in accordance with claim 10, wherein the disease is Alzheimer's disease.
PCT/US2003/011316 2002-04-12 2003-04-14 Prevention of brain inflammation as a result of induced autoimmune response WO2003086310A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/510,820 US20070134247A9 (en) 2002-04-12 2003-04-14 Prevention of brain inflammation as a result of induced autoimmune response
AU2003226356A AU2003226356A1 (en) 2002-04-12 2003-04-14 Prevention of brain inflammation as a result of induced autoimmune response
US12/467,931 US20090280114A1 (en) 2002-04-12 2009-05-18 Prevention of brain inflammation as a result of induced autoimmune response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37171902P 2002-04-12 2002-04-12
US60/371,719 2002-04-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/467,931 Continuation-In-Part US20090280114A1 (en) 2002-04-12 2009-05-18 Prevention of brain inflammation as a result of induced autoimmune response

Publications (2)

Publication Number Publication Date
WO2003086310A2 true WO2003086310A2 (en) 2003-10-23
WO2003086310A3 WO2003086310A3 (en) 2004-02-19

Family

ID=29250730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/011316 WO2003086310A2 (en) 2002-04-12 2003-04-14 Prevention of brain inflammation as a result of induced autoimmune response

Country Status (3)

Country Link
US (1) US20070134247A9 (en)
AU (1) AU2003226356A1 (en)
WO (1) WO2003086310A2 (en)

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036291A3 (en) * 2004-07-30 2006-07-20 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
WO2006113347A3 (en) * 2005-04-13 2006-12-21 Univ Tennessee Res Foundation Diagnostic and therapeutic potential of immune globulin intravenous (igiv) products
WO2007027714A2 (en) 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
WO2006118959A3 (en) * 2005-04-29 2007-05-10 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EP1766396A4 (en) * 2004-06-07 2007-06-20 Univ Ramot Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
WO2008030251A1 (en) * 2006-09-08 2008-03-13 Georgetown University Deglycosylated anti-amyloid beta antibodies
WO2008076321A1 (en) 2006-12-14 2008-06-26 Schering Corporation Engineered anti-tslp antibody
WO2008106134A2 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
WO2010071800A1 (en) 2008-12-19 2010-06-24 Schering Corporation Feed supplement for mammalian cell culture and methods of use
WO2010100056A2 (en) 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
EP2322219A2 (en) 2005-09-01 2011-05-18 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012004367A1 (en) 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27
EP2417974A1 (en) 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
EP2426144A1 (en) 2007-02-23 2012-03-07 Schering Corporation Engineered anti-IL-23p19 antibodies
EP2426145A1 (en) 2007-02-23 2012-03-07 Schering Corporation Engineered anti-IL-23p19 antibodies
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2015016718A1 (en) 2013-08-02 2015-02-05 Bionovion Holding B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
WO2015026684A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Modulation of tumor immunity
WO2015032906A2 (en) 2013-09-05 2015-03-12 Bionovion Holding B.V. Cd70-binding peptides and method, process and use relating thereto
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2016028672A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
EP3023438A1 (en) 2009-09-03 2016-05-25 Merck Sharp & Dohme Corp. Anti-gitr antibodies
WO2016110587A1 (en) 2015-01-09 2016-07-14 Aduro Biotech Holdings, Europe B.V. Altered april binding antibodies
WO2017075124A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2017184562A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
WO2018020476A1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings, Europe B.V. Anti-pd-1 antibodies
WO2018025178A1 (en) 2016-08-02 2018-02-08 Aduro Biotech Holdings, Europe B.V. Antibodies against human ctla-4
WO2018058022A1 (en) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
WO2018187518A1 (en) 2017-04-07 2018-10-11 Merck Sharp & Dohme Corp. Anti-ilt4 antibodies and antigen-binding fragments
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2019129137A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-lag-3 antibody and uses thereof
WO2019129136A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-pd-l1 antibody and uses thereof
WO2019152642A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019168403A2 (en) 2018-03-02 2019-09-06 Labo Bio-Medical Investments B.V. Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2020056077A1 (en) 2018-09-13 2020-03-19 The Board Of Regents Of The University Of Texas System Novel lilrb4 antibodies and uses thereof
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
WO2020092233A1 (en) 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. Anti-human pd-1 antibody crystals and methods of use thereof
WO2021183839A2 (en) 2020-03-12 2021-09-16 Immune-Onc Therapeutics, Inc. Novel anti-lilrb4 antibodies and derivative products
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
WO2021219871A2 (en) 2020-04-30 2021-11-04 Aduro Biotech Holdings, Europe B.V. Anti-cd103 antibodies
WO2021262791A1 (en) 2020-06-25 2021-12-30 Merck Sharp & Dohme Corp. High affinity antibodies targeting tau phosphorylated at serine 413
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
WO2022066832A1 (en) 2020-09-24 2022-03-31 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
WO2022165001A1 (en) 2021-01-29 2022-08-04 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
US11512131B2 (en) 2017-12-27 2022-11-29 Innovent Biologies (Suzhou) Co., Ltd. Anti-PD-L1 antibody and uses thereof
US11633476B2 (en) 2017-05-02 2023-04-25 Merck Sharp & Dohme Llc Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
US11959924B2 (en) 2013-09-06 2024-04-16 Aduro Biotech Holdings, Europe B.V. Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
US11998526B2 (en) 2019-12-17 2024-06-04 Chinook Therapeutics, Inc. Methods of improving renal function
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
US12122834B2 (en) 2018-02-01 2024-10-22 Merck Sharp & Dohme Llc Anti-PD-1 antibodies
US12319735B2 (en) 2018-11-07 2025-06-03 Merck Sharp & Dohme Llc Co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
EP4623930A2 (en) 2020-12-03 2025-10-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225636A1 (en) * 2002-03-05 2003-09-22 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
BRPI0619748B8 (en) * 2005-12-12 2021-05-25 Ac Immune Sa monoclonal antibody, polynucleotide, composition, mixture, use of a monoclonal antibody or a functional part thereof, method for preparing a pharmaceutical composition, isolated hybridoma cell line, method of diagnosing a disease or condition associated with amyloid in a patient, method to diagnose a predisposition to a disease or condition, method to monitor minimal residual disease, method to predict a patient's responsiveness, and test kits
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
DK2170389T3 (en) * 2007-06-12 2015-01-19 Ac Immune Sa Humanized antibodies against amyloid beta
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
ES2609918T3 (en) * 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in eye diseases
SI2238166T1 (en) * 2007-10-05 2014-03-31 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease

Cited By (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766396A4 (en) * 2004-06-07 2007-06-20 Univ Ramot Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
EP2298807A2 (en) 2004-07-30 2011-03-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006036291A3 (en) * 2004-07-30 2006-07-20 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EA016357B1 (en) * 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Antibodies directed against amyloid-beta peptide and methods using same
EP2298807A3 (en) * 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006113347A3 (en) * 2005-04-13 2006-12-21 Univ Tennessee Res Foundation Diagnostic and therapeutic potential of immune globulin intravenous (igiv) products
KR101130874B1 (en) 2005-04-29 2012-03-28 리나트 뉴로사이언스 코퍼레이션 Antibodies directed against amyloid-beta peptide and methods using same
WO2006118959A3 (en) * 2005-04-29 2007-05-10 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
TWI501975B (en) * 2005-04-29 2015-10-01 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
CN102617733B (en) * 2005-04-29 2016-01-20 瑞纳神经科学公司 Antibodies directed against amyloid-beta peptide and using method thereof
AU2006242546B2 (en) * 2005-04-29 2011-04-21 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
EA016193B1 (en) * 2005-04-29 2012-03-30 Ринат Ньюросайенс Корп. Antibodies directed against amyloid-beta peptide and methods using same
CN102617733A (en) * 2005-04-29 2012-08-01 瑞纳神经科学公司 Antibodies directed against amyloid-beta peptide and methods using same
EA016193B9 (en) * 2005-04-29 2012-08-30 Ринат Ньюросайенс Корп. Antibodies directed against amyloid-beta peptide and methods using same
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
WO2007027714A2 (en) 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
EP2322219A2 (en) 2005-09-01 2011-05-18 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
WO2008030251A1 (en) * 2006-09-08 2008-03-13 Georgetown University Deglycosylated anti-amyloid beta antibodies
WO2008076321A1 (en) 2006-12-14 2008-06-26 Schering Corporation Engineered anti-tslp antibody
EP2628752A1 (en) 2006-12-14 2013-08-21 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
EP2426145A1 (en) 2007-02-23 2012-03-07 Schering Corporation Engineered anti-IL-23p19 antibodies
EP2426144A1 (en) 2007-02-23 2012-03-07 Schering Corporation Engineered anti-IL-23p19 antibodies
EP2417974A1 (en) 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
EP2395025A1 (en) 2007-02-28 2011-12-14 Schering Corporation Engineered Anti-IL-23R Antibodies
WO2008106134A2 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2481408A2 (en) 2007-03-01 2012-08-01 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2010071800A1 (en) 2008-12-19 2010-06-24 Schering Corporation Feed supplement for mammalian cell culture and methods of use
EP4147719A1 (en) 2009-03-02 2023-03-15 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (april)
WO2010100056A2 (en) 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
EP3199551A2 (en) 2009-07-31 2017-08-02 E. R. Squibb & Sons, L.L.C. Fully human antibodies to btla
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
EP3023438A1 (en) 2009-09-03 2016-05-25 Merck Sharp & Dohme Corp. Anti-gitr antibodies
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012004367A1 (en) 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
EP3398612A1 (en) 2011-03-31 2018-11-07 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2015016718A1 (en) 2013-08-02 2015-02-05 Bionovion Holding B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
WO2015026684A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Modulation of tumor immunity
EP3770175A2 (en) 2013-08-20 2021-01-27 Merck Sharp & Dohme Corp. Modulation of tumor immunity
WO2015032906A2 (en) 2013-09-05 2015-03-12 Bionovion Holding B.V. Cd70-binding peptides and method, process and use relating thereto
US11959924B2 (en) 2013-09-06 2024-04-16 Aduro Biotech Holdings, Europe B.V. Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample
EP3834842A1 (en) 2014-08-19 2021-06-16 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
WO2016028672A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
EP4029879A1 (en) 2015-01-09 2022-07-20 Aduro Biotech Holdings, Europe B.V. Altered april binding antibodies
US12145992B2 (en) 2015-01-09 2024-11-19 Aduro Biotech Holdings, Europe B.V. Method of treating IgA nephropathy by administering altered antibodies which bind human a proliferation-inducing ligand (APRIL) protein
US10961316B2 (en) 2015-01-09 2021-03-30 Aduro Biotech Holdings, Europe B.V. Humanized antibodies which bind to human APRIL (“a proliferation-inducing ligand”)
WO2016110587A1 (en) 2015-01-09 2016-07-14 Aduro Biotech Holdings, Europe B.V. Altered april binding antibodies
US9969808B2 (en) 2015-01-09 2018-05-15 Aduro Biotech Holdings, Europe B.V. Altered APRIL binding antibodies
US9963500B2 (en) 2015-10-29 2018-05-08 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus
US10072072B2 (en) 2015-10-29 2018-09-11 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus
US11566065B2 (en) 2015-10-29 2023-01-31 Merck Sharp & Dohme Llc Antibody neutralizing human respiratory syncytial virus
US10323079B2 (en) 2015-10-29 2019-06-18 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus
US11981726B2 (en) 2015-10-29 2024-05-14 Merck Sharp & Dohme Llc Antibody neutralizing human respiratory syncytial virus
US10358480B2 (en) 2015-10-29 2019-07-23 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus
WO2017075124A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus
US11008380B2 (en) 2015-10-29 2021-05-18 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus
US12371478B2 (en) 2015-10-29 2025-07-29 Merck Sharp & Dohme Llc Antibody neutralizing human respiratory syncytial virus
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2017184562A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
US10494436B2 (en) 2016-07-29 2019-12-03 Aduro Biotech Holdings, Europe B.V. Anti-PD-1 antibodies
WO2018020476A1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings, Europe B.V. Anti-pd-1 antibodies
WO2018025178A1 (en) 2016-08-02 2018-02-08 Aduro Biotech Holdings, Europe B.V. Antibodies against human ctla-4
US10808030B2 (en) 2016-08-02 2020-10-20 Aduro Biotech Holdings, Europe B.V. Anti-HCTLA-4 antibodies
WO2018058022A1 (en) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
US12344670B2 (en) 2017-04-07 2025-07-01 Agenus Inc. Anti-ILT4 antibodies and antigen-binding fragments
US11053315B2 (en) 2017-04-07 2021-07-06 Merck Sharp & Dohme Corp. Anti-ILT4 antibodies and antigen-binding fragments
WO2018187518A1 (en) 2017-04-07 2018-10-11 Merck Sharp & Dohme Corp. Anti-ilt4 antibodies and antigen-binding fragments
US11897957B2 (en) 2017-04-07 2024-02-13 Merck Sharp & Dohme Llc Anti-ILT4 antibodies and antigen-binding fragments
US11897956B2 (en) 2017-04-07 2024-02-13 Merck Sharp & Dohme Llc Anti-ILT4 antibodies and antigen-binding fragments
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
US11633476B2 (en) 2017-05-02 2023-04-25 Merck Sharp & Dohme Llc Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
WO2019129136A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-pd-l1 antibody and uses thereof
WO2019129137A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-lag-3 antibody and uses thereof
US11512131B2 (en) 2017-12-27 2022-11-29 Innovent Biologies (Suzhou) Co., Ltd. Anti-PD-L1 antibody and uses thereof
US12122834B2 (en) 2018-02-01 2024-10-22 Merck Sharp & Dohme Llc Anti-PD-1 antibodies
WO2019152642A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US11072658B2 (en) 2018-02-01 2021-07-27 Merck Sharp & Dohme Corp. Anti-PD-1/LAG3 bispecific antibodies
WO2019168403A2 (en) 2018-03-02 2019-09-06 Labo Bio-Medical Investments B.V. Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2020056077A1 (en) 2018-09-13 2020-03-19 The Board Of Regents Of The University Of Texas System Novel lilrb4 antibodies and uses thereof
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
WO2020092233A1 (en) 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. Anti-human pd-1 antibody crystals and methods of use thereof
US12319735B2 (en) 2018-11-07 2025-06-03 Merck Sharp & Dohme Llc Co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
US11998526B2 (en) 2019-12-17 2024-06-04 Chinook Therapeutics, Inc. Methods of improving renal function
US12370174B2 (en) 2019-12-17 2025-07-29 Chinook Therapeutics, Inc. Methods of improving renal function
US12121509B2 (en) 2019-12-17 2024-10-22 Chinook Therapeutics, Inc. Methods of improving renal function
WO2021183839A2 (en) 2020-03-12 2021-09-16 Immune-Onc Therapeutics, Inc. Novel anti-lilrb4 antibodies and derivative products
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
WO2021219871A2 (en) 2020-04-30 2021-11-04 Aduro Biotech Holdings, Europe B.V. Anti-cd103 antibodies
WO2021262791A1 (en) 2020-06-25 2021-12-30 Merck Sharp & Dohme Corp. High affinity antibodies targeting tau phosphorylated at serine 413
WO2022066832A1 (en) 2020-09-24 2022-03-31 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
EP4623930A2 (en) 2020-12-03 2025-10-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
WO2022165001A1 (en) 2021-01-29 2022-08-04 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies

Also Published As

Publication number Publication date
AU2003226356A1 (en) 2003-10-27
WO2003086310A3 (en) 2004-02-19
AU2003226356A8 (en) 2003-10-27
US20060008458A1 (en) 2006-01-12
US20070134247A9 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
US20060008458A1 (en) Prevention of brain inflammation as a result of induced autoimmune response
Cotchett et al. Comparison of the efficacy and safety of anti-CD20 B cells depleting drugs in multiple sclerosis
AU2021202095B9 (en) Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
Arsura Experience with intravenous immunoglobulin in myasthenia gravis
Dodel et al. Intravenous immunoglobulins as a treatment for Alzheimer’s disease: rationale and current evidence
AU2007238677B2 (en) Use of IL-I antibodies for treating ophthalmic disorders
US8734799B2 (en) Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
EP2430051B1 (en) Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases
KR20100135807A (en) Disease Remedy
CN118001391A (en) Methods of treating allergies and enhancing allergen-specific immunotherapy with IL-4R inhibitors
Ali et al. Inebilizumab-cdon: USFDA approved for the treatment of NMOSD (neuromyelitis optica spectrum disorder)
Jonker et al. Successful treatment of EAE in rhesus monkeys with MHC class II specific monoclonal antibodies
Ovchinnikov et al. An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
Calogiuri et al. Hypersensitivity reactions to last generation chimeric, umanized and human recombinant monoclonal antibodies for therapeutic use
JP2015516980A (en) Combination of CD37 antibody and bendamustine
US20090280114A1 (en) Prevention of brain inflammation as a result of induced autoimmune response
JPWO2021224499A5 (en)
Ferrero et al. High-dose intravenous immunoglobulin G treatment of myasthenia gravis
JP3973360B2 (en) CD25 binding molecule for use in the treatment of rheumatoid arthritis or skin diseases
Jacob Complement inhibition in Myasthenia–from basics to RCT data
RU2024103383A (en) METHODS FOR TREATING NEUROLOGICAL DISEASES
Brown et al. Refining an Alzheimer’s vaccine to avoid an inflammatory response
RU2025102601A (en) COMBINATIONS OF HETERODIMERIC Fc-FUSION PROTEINS IL15/IL15Rα AND BISPECIFIC ANTIBODIES FcRH5xCD3 FOR THE TREATMENT OF BLOOD CANCER TYPES
JPWO2019213468A5 (en)
WO2025128264A1 (en) Anti-pd-1 monoclonal antibody and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
ENP Entry into the national phase

Ref document number: 2006008458

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007134247

Country of ref document: US

Ref document number: 10510820

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10510820

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载